(Q37854083)

24 August 2017

1 reference

title

Sorafenib-induced premalignant and malignant skin lesions (English)

1 reference

24 August 2017

Victoria L Williams

1

1 reference

24 August 2017

Philip R Cohen

series ordinal

2

1 reference

24 August 2017

David J Stewart

series ordinal

3

1 reference

24 August 2017

publication date

1 April 2011

1 reference

International Journal of Dermatology

24 August 2017

published in

1 reference

24 August 2017

volume

50

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

396-402

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Array of cutaneous adverse effects associated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Keratoacanthomas associated with sorafenib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

The histologic spectrum of epithelial neoplasms induced by sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

The risk of progression to invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Differences in sialyl-Tn antigen expression between keratoacanthomas and cutaneous squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Non-melanoma skin cancer: what drives tumor development and progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Human papillomaviruses and non-melanoma skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

Keratoacanthoma: a clinico-pathologic enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04822.X

10.1111/J.1365-4632.2010.04822.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference